Ibrutinib is indicated for the treatment of patients with chronic lymphocytic leukaemia who have received ≥1 prior therapy, or as a first-line treatment in the presence of del(17p) or TP53 mutation in patients not suitable for chemoimmunotherapy.
|07/11/2014||18/12/2014||Full Pharmacoeconomic Evaluation Recommended.|
|02/04/2015||01/10/2015||Reimbursement Not recommended|
The cost effectiveness of ibrutinib (Imbruvica®) in the treatment of patients with CLL who have received ≥1 prior therapy, or as a first-line treatment in the presence of del(17p)/TP53 mutation in patients not suitable for chemo-immunotherapy, has not been demonstrated and therefore it is not recommended for reimbursement at the submitted price.
The HSE has approved reimbursement following confidential price negotiations.